Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab in metastatic biliary tract cancer as second-line treatment with integrated genomic analysis
KCT0003948Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in biliary cancer, sponsored by Merck & Co.. Started Feb 2018; status: recruiting.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0003948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003948.